Q1 EPS Estimates for AngioDynamics Lowered by HC Wainwright

AngioDynamics, Inc. (NASDAQ:ANGO) – Analysts at HC Wainwright lowered their Q1 2027 earnings per share estimates for shares of AngioDynamics in a note issued to investors on Wednesday, July 15th. HC Wainwright analyst Y. Chen now forecasts that the medical instruments supplier will post earnings of ($0.11) per share for the quarter, down from their prior forecast of ($0.05). HC Wainwright has a “Buy” rating and a $19.00 price objective on the stock. The consensus estimate for AngioDynamics’ current full-year earnings is ($0.26) per share. HC Wainwright also issued estimates for AngioDynamics’ Q2 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.06) EPS and FY2027 earnings at ($0.27) EPS.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The firm had revenue of $86.61 million for the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS.

Several other analysts have also recently issued reports on ANGO. Freedom Capital upgraded shares of AngioDynamics to a “strong-buy” rating in a research note on Monday, April 6th. Zacks Research lowered shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 30th. Canaccord Genuity Group upped their price target on shares of AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $19.50.

AngioDynamics Trading Down 2.3%

Shares of NASDAQ:ANGO opened at $14.14 on Friday. The company has a 50 day moving average of $12.19 and a 200 day moving average of $11.34. The stock has a market cap of $584.41 million, a P/E ratio of -16.25 and a beta of 0.34. AngioDynamics has a 12 month low of $8.36 and a 12 month high of $15.20.

Hedge Funds Weigh In On AngioDynamics

A number of institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE raised its position in shares of AngioDynamics by 262.7% during the 1st quarter. Bank of America Corp DE now owns 503,640 shares of the medical instruments supplier’s stock valued at $5,726,000 after buying an additional 364,763 shares in the last quarter. Quantinno Capital Management LP grew its position in AngioDynamics by 15.0% in the first quarter. Quantinno Capital Management LP now owns 43,539 shares of the medical instruments supplier’s stock worth $495,000 after acquiring an additional 5,675 shares in the last quarter. Lazard Asset Management LLC grew its position in AngioDynamics by 1,328.2% in the first quarter. Lazard Asset Management LLC now owns 154,578 shares of the medical instruments supplier’s stock worth $1,758,000 after acquiring an additional 143,755 shares in the last quarter. Paradigm Capital Management Inc. NY increased its stake in AngioDynamics by 5.9% in the first quarter. Paradigm Capital Management Inc. NY now owns 718,200 shares of the medical instruments supplier’s stock valued at $8,166,000 after acquiring an additional 40,000 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its stake in AngioDynamics by 0.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 758,450 shares of the medical instruments supplier’s stock valued at $8,624,000 after acquiring an additional 5,509 shares during the last quarter. Institutional investors own 89.43% of the company’s stock.

More AngioDynamics News

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: AngioDynamics posted record fiscal Q4 and full-year results, with revenue growth, an earnings beat, and expanding gross margin, all of which support the bullish move in the stock. AngioDynamics Q4 Earnings Beat Estimates, Gross Margin Expands
• Positive Sentiment: The company raised its fiscal 2027 sales outlook, suggesting management sees continued momentum in demand and execution. AngioDynamics tops revenue forecasts and raises sales outlook for fiscal 2027 (ANGO)
• Neutral Sentiment: HC Wainwright raised its price target to $19 and kept a Buy rating, reinforcing the stock’s upside case even though the move also reflects that the shares have already appreciated meaningfully. HC Wainwright raised its price target on AngioDynamics
• Negative Sentiment: HC Wainwright also trimmed its Q4 2027 earnings estimate to $0.01 from $0.05, indicating analysts still see only modest near-term profit generation despite the improved outlook. AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade)

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.